About CITR

Horizontal Tabs

About CITR

Initiated and funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), CITR was founded in September 2001. The Registry is coordinated by The Emmes Corporation of Rockville, Maryland, with Dr. Bernhard Hering of the University of Minnesota as the Medical Director.

The CITR Executive Committee is composed of Dr. Michael Appel (NIDDK), Dr. Donald Stablein (EMMES), Franca Benedicty Barton (EMMES), Dr. Bernhard Hering (University of Minnesota), Dr. Michael Rickels (University of Pennsylvania), and Dr. Rodolfo Alejandro (University of Miami). A Scientific Advisory Committee of seven members, chosen by EMMES in consultation with NIDDK, provides scientific direction to the Registry with Dr. Hering presiding as the Chairman. Members include Dr. Michael Cecka (UCLA), Dr. Philip E. Cryer (Washington University School of Medicine), Dr. Mary D. Ellison (United Network for Organ Sharing or UNOS), Dr. Jerry Palmer (Puget Sound Health Care Systems), Dr. Camillo Ricordi (University of Miami), and Dr. Olle Korsgren (Uppsala University, Sweden and the Nordic Network).

Islet/beta cell transplantation is a complex procedure with many factors contributing to the outcome. Compiling and analyzing data from all transplant centers in the US, Canada, as well as some European and Australian centers will accelerate the identification of both critical risk factors and key determinants of success and thereby guide transplant centers in developing and refining islet/beta cell transplant protocols.

Islet/beta cell transplantation has become a rapidly developing field, making it difficult for non-experts to stay abreast of the most recent information. Data communicated by CITR will assist people with diabetes, health care professionals, payers and providers, professional societies, funding agencies, and governmental institutions in making decisions regarding islet/beta cell transplantation.

The inclusion of the term “collaborative” in the name of the Registry emphasizes the importance of collaboration in fulfilling the CITR mission and goals. Close collaboration with the transplant centers will ensure that relevant questions are addressed, that data submitted are accurate and complete, and that the needs of the transplant community are served. Collaboration with other initiatives, programs, and networks of the National Institutes of Health (e.g., the Human Pancreatic Islet Cell Resource (HPICR), the Immune Tolerance Network (ITN), and the Clinical Islet Transplant Consortium (CIT)), and the Juvenile Diabetes Research Foundation International (JDRFI), will be instrumental in utilizing established infrastructures and in facilitating ancillary studies. Collaboration with the diabetes care community, the health insurance industry, the Centers for Medicare and Medicaid Services (formerly known as Health Care Finance Administration - HCFA), Health Resources and Services Administration (HRSA), and the Food and Drug Administration (FDA) will ensure that the outcome measures used by CITR are appropriate, standardized, and relevant. Collaboration with the United Network for Organ Sharing (UNOS) and the Canadian Organ Replacement Register (CORR) will avoid duplication of efforts with respect to the collection of donor and recipient information. Finally, collaboration with the International Islet Transplant Registry (ITR) in Giessen, Germany, will ensure that the worldwide status of islet/beta cell transplantation is regularly updated.

CITR's Goals

    
The CITR goals are:

  • To develop and implement standards for reporting islet/beta cell transplants and their outcome.
  • To collect and compile data on all islet/beta cell transplants in human recipients performed in North America, as well as some European and Australian centers.
  • To increase the safety of islet/beta cell transplantation by distributing electronically the pertinent information of submitted serious adverse event reports to all participating clinical centers in a timely fashion.
  • To perform scientific analysis on islet/beta cell transplant data, with particular emphasis on:
    • Safety of islet/beta cell transplant product and procedure and protocol-regulated treatment products
    • Number of islet/beta cell transplants and retransplants performed, categorized by transplant institution, donor tissue source and handling, recipient category, transplant technique and site, and recipient treatment protocols
    • Efficacy of islet/beta cell transplants as defined by standardized outcome measures and as determined by donor factors, recipient demographics, donor-recipient matching, islet/beta cell processing and product characteristics, transplant technique and site, recipient treatment, and post-transplant events
  • To communicate comprehensive and current information on islet/beta cell transplantation to transplant institutions, the diabetes and general health care community, and the interested general public via the CITR web site (http://www.citregistry.org), publications, and presentations.
  • To stimulate prospective and retrospective studies on emerging issues of importance.

 

CITR's Mission

The mission of the Collaborative Islet Transplant Registry (CITR) is to expedite progress and promote safety in islet/beta cell transplantation through the collection, analysis, and communication of comprehensive and current data on all islet/beta cell transplants performed in North America, as well as some European and Australian centers.

Protocols